"Sunshine, Psychedelics & Cybin" $CYBN $MNMD $CMPS encodelp.com/coverage-unive…

Dodging, Data, and Delays: FDA, $CYBN, $EPRX & $CLRB encodelp.com/coverage-unive…

$TARA

Protara $TARA Inserts Itself Into NMIBC Discussion $CGON $ENGN $PIRS Madeleine Armstrong Biotech Hangout encodelp.com/coverage-unive…

$MSCL.TO $MSCLF

FDA's Imminent BMD Decision $ENTX encodelp.com/coverage-unive…

FDA scheduled to make 1st biomarker qualification decision youtube.com/watch?v=vc-_C-…

In the coming days, the FDA is expected to make a decision for bone mineral density (BMD) as a surrogate endpoint for future osteoporosis drug approvals. $ENTX EB613 is prepared to leverage this potential new pathway. Phase 3 expected to be initiated in H2 2025 in the US and EU.

Trading Sideways: Better Days Ahead For Two Data-Rich Stories? $VTYX $TARA encodelp.com/coverage-unive…

Tailwinds & Tardiness: FDA, Cybin & Entera $GHRS $CYBN $ENTX encodelp.com/coverage-unive…

Near-Term Data, Plump Balance Sheets & Calling It: Nektar, Ventyx & Xenon $NKTR $VTYX $XENE Adam May encodelp.com/coverage-unive…

Likeness: Bright Minds, Delcath, Novocure, Trisalus...RenovoRx $DRUG $DCTH $NVCR $TLSI $RNXT encodelp.com/coverage-unive…

Franchise Building: Xenon & Delcath $XENE $DCTH encodelp.com/coverage-unive…

Protara's Small Sample But Big Potential & Rezolute's Rebound $TARA $CGON $RZLT encodelp.com/coverage-unive…

Decoding Q1: Insights on $XENE, $DCTH, $RNXT, and $FENC encodelp.com/coverage-unive…

Expectations For Impending June Data From $NKTR, $VTYX & $CMPS / $CYBN encodelp.com/coverage-unive…

$VRNA $DCTH

Degrees of Good: Data From Nektar, Compass, and Ventyx $NKTR $CMPS $CYBN $VTYX encodelp.com/coverage-unive…

$VRNA Rosalind Dec 2021

Ovid and Xenon: Too Early To Draw Parallels? $OVID $XENE $DCTH encodelp.com/coverage-unive…